According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
It’s similar in concept to Casgevy, an approved medicine from Vertex Pharmaceuticals, but uses a different ... Jacob Bell ...
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback